Načítá se...
Lipid‐lowering response of the HMG‐CoA reductase inhibitor fluvastatin is influenced by polymorphisms in the low‐density lipoprotein receptor gene in Brazilian patients with primary hypercholesterolemia
Although the efficacy of fluvastatin (HMG‐CoA reductase inhibitor) in the treatment of primary hypercholesterolemia is well documented, a wide interindividual variation treatment response has been observed. We have studied the possible role of the AvaII (exon 13), HincII (exon 12), and PvuII (intron...
Uloženo v:
| Vydáno v: | J Clin Lab Anal |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley & Sons, Inc.
2000
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6807834/ https://ncbi.nlm.nih.gov/pubmed/10797611 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/(SICI)1098-2825(2000)14:3<125::AID-JCLA7>3.0.CO;2-S |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|